Liquidia Corporation - Common Stock (LQDA)

Liquidia Corp (LQDA) exemplifies a high-growth momentum stock in a strong technical uptrend, combining surging revenue with a top-rated chart pattern.

One fund just walked away from a rising offshore driller—here’s what long-term investors should make of the move.

A fast-growing niche segment may be the real reason this small-cap consumer products stock is drawing new institutional attention.

One small fund’s high-conviction move offers a window into how specialists are navigating 2025’s biotech rally.

This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of commercialization.

Liquidia (LQDA) stock shows a powerful technical uptrend and explosive 1,121% revenue growth, aligning with the high-momentum Minervini strategy.

Liquidia's Q3 2025 results crushed expectations with $54.3M revenue, driven by the successful launch of YUTREPIA. The stock surged as the company moves toward profitability.

Insmed stock surged early Thursday as Argenx stock rose more moderately. The top-notch biotech companies beat third-quarter calls.

The company sells Tyvaso, a treatment for lung diseases. On Tuesday, Tyvaso showed promise, again, in a chronic condition.

Liquidia Q2 sales hit $8.84 million after Yutrepia launch; PH-ILD study shows stable tolerability and improved walking distance at week 16.

The company is working through a patent battle that could seriously hamper sales of its new drug.

Shares are trading at a 25-year high ahead of what could be the first approval for a drug with a massive pipeline in front of it.